Senior Vice President, Late-Stage Clinical Development

Revolution Medicines•Redwood City, CA

3d•Hybrid

About The Position

The Senior Vice President, Late-Stage Clinical Development is a senior leadership role responsible for shaping and driving Revolution Medicines’ late-stage clinical development strategy across its RAS(ON) portfolio. Reporting to the Chief Medical Officer, the executive leads the registrational and Phase 3 programs across the company’s assets as the organization expands from one approved product to a multi-asset, multi-indication late-stage portfolio. The role works with the Chief Medical Officer to create an integrated development plan and helps determine how the portfolio evolves and creates value. The executive works through Global Development Team Leads to shape trials, interpret emerging data, and develop approaches intended to change standards of care in difficult-to-treat tumors. The role includes building and developing the late-stage organization, including hiring and supporting team leads who build their own teams and aligning clinical scientists with the programs they support. The position partners with the Chief Medical Officer and Chief Development Officer on portfolio strategy, and collaborates with research, regulatory, biometrics, commercial, and regulatory affairs teams. The executive represents the company with clinical collaboration partners and may co-chair a joint steering or joint development committee. The role may also take leadership of a disease-area franchise, with scope expected to grow as the organization and portfolio expand.

Requirements

MD or MD/PhD, trained as a medical oncologist.
Substantial late-stage oncology development experience, including accountability for registrational and Phase 3 programs and global regulatory filings.
Track record leading development teams across multiple concurrent assets.
Demonstrated ability to build and structure a clinical development organization, including hiring program leaders and building teams beneath them.
Strong scientific judgment and credibility to guide experienced development leaders.
Ability to operate effectively in a fast-moving, evolving organization and build alignment across senior stakeholders.
Motivation to make pipeline impact and change the standard of care in difficult tumors.

Nice To Haves

Depth in pancreatic, colorectal, or lung cancer is strongly preferred.

Responsibilities

Drive late-stage clinical development strategy across the RAS(ON) portfolio and develop an integrated company development plan with the Chief Medical Officer.
Own registrational and Phase 3 trials across all programs and assets, from design through readout and submission support.
Shape indication sequencing, study design, endpoint selection, and combination strategy with research, regulatory, biometrics, and commercial leadership.
Lead, develop, and grow the Global Development Team Leads, and guide the construction and defense of their clinical development plans.
Build a late-stage organization with clear program ownership, structured so team leads hire and lead their own teams.
Partner with regulatory affairs on global filings, health authority interactions, and lifecycle planning.
Partner with the Chief Medical Officer and Chief Development Officer on portfolio strategy and prioritization.
Represent the company with clinical collaboration partners, with the potential to co-chair a joint steering or joint development committee.
Engage investigators, key opinion leaders, and the broader oncology community on the company’s late-stage programs and data.